RSS

DBV Technologies

DBV Technologies has announced the initiation of a Phase three study designed to evaluate the safety and efficacy of Viaskin Peanut 250g in children ages 4 to 11 with peanut allergies more

News

The FDA has accepted an investigator-sponsored investigational new drug application for a Phase IIA clinical trial for the potential treatment of milk-induced eosinophilic esophagitis in children using DBV Technologies' Viaskin milk. more

News